A similar conclusion could be reached from immunopharmacological experiments using a pan-neutralizing TGF-β antibody, highlighting TGF-β as an attractive drug candidate for the treatment of diabetes that may accompany PDAC. Here, TGFB1 is linked to diabetes mellitus.